![]() ![]() ![]() Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s other filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site ( Opens a new window). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Although these statements are based on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and you should not place undue reliance on them. By their nature, forward-looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. Horizon Therapeutics plc HZNP announced the failure of the phase II study evaluating daxdilimab for the treatment of systemic lupus erythematosus (SLE) to meet its primary endpoint of low SLE. Horizon primarily markets products in the United States, which represented 97 of Horizon's 2019 worldwide sales. And the clearest expression of that purpose is the portfolio of medicines we offer to treat rare, autoimmune and severe inflammatory diseases. At Horizon, were driven by a clear purpose: to improve patients’ lives. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. Horizon Therapeutics Public Ltd Co is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. We go to incredible lengths to help patients live healthier lives. Private Securities Litigation Reform Act of 1995. ICON is the worlds leading clinical research organisation, providing outsourced clincal development and commercialisation services to the pharmaceutical. Horizon Therapeutics Public Limited Company (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) I re l an d 001-35238 N ot A p p l i c ab l e (State or othe r jur i s di c ti on of i nc or por ati on) (Commi s s i on F i l e No.) (I RS E mpl oye r I de nti fi c ati on No.) 70 S t. Any statements set forth on this website that are not historical facts are considered “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |